Bristol Myers Squibb Reports Phase 2b Data for Baricitinib in HIV

Bristol Myers Squibb today announced Phase 2b results for baricitinib in patients with HIV. The study demonstrated that baricitinib improves quality of life compared to standard of care or placebo. These results provide important insights into the treatment of HIV and support the continued development of baricitinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.